Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast – 2030

Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast - 2030

DelveInsight’s “Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Progressive Supranuclear Palsy, historical and forecasted epidemiology as well as the Progressive Supranuclear Palsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast—2030

DelveInsight launched a new report on Progressive Supranuclear Palsy Market Insights, Epidemiology and Market Forecast-2030
Some of the key facts of the report

• Total Progressive Supranuclear Palsy (PSP) prevalent cases in 7 MM was 98,498 in 2017.
• The prevalence of PSP in Japan in 2017 was 21,869.
• The prevalence of PSP in the United States in 2017 was 20,161.
• The prevalence of PSP in the United Kingdom was 12,681 in 2017.
• Males are affected by PSP more as compared to females.

Key benefits of the report
1. Progressive Supranuclear Palsy market report covers a descriptive overview and comprehensive insight of the Progressive Supranuclear Palsy epidemiology and Progressive Supranuclear Palsy market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Progressive Supranuclear Palsy market report provides insights into the current and emerging therapies.
3. Progressive Supranuclear Palsy market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Progressive Supranuclear Palsy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Progressive Supranuclear Palsy market.

Request for sample pages

“The therapeutic market of Progressive Supranuclear Palsy in 7MM in 2017- USD 10.54 million”.


Progressive Supranuclear Palsy (PSP) also called Steele-Richardson-Olszewski syndrome, an uncommon brain disorder, which affects movement, control of walking (gait) and balance, speech, swallowing,vision, mood and behaviour, and thinking. The cause of PSP is unknown, but it is a form of tauopathy, in which abnormal phosphorylation of the protein tau leads to the destruction of vital protein filaments in nerve cells, causing their death.
Progressive Supranuclear Palsy treatment is symptomatic and supportive. No cure for the disease is there at present. Some of the older types of antidepressants like amitriptyline, fluoxetine, and imipramine, can also help relieve symptoms of Progressive Supranuclear Palsy.
Walking aids like a walker weighted in front and wearing shoes with built-up heels may help in preventing affected individuals from falling backwards. Bifocals or special glasses with prisms may be prescribed for some individuals with PSP to treat certain difficulties in eyesight (i.e., difficulty looking down).

The launch of the emerging therapies is expected to significantly impact Progressive Supranuclear Palsy treatment scenario in the upcoming years:-
Drugs covered
• AZP2006
• UCB0107
• ASN120290
And many others

The key players in Progressive Supranuclear Palsy market are:
• AlzProtect
• UCB Biopharma
• Asceneuron Therapeutics
• TauRx Pharmaceuticals

And many others

Table of contents

1. Report Introduction

2. Progressive Supranuclear Palsy Market Overview at a Glance

3. PSP Disease Background and Overview

4. Progressive Supranuclear Palsy Epidemiology and Patient Population

5. Progressive Supranuclear Palsy Epidemiology by Countries (2017–2030)

5.1. United States

5.2. EU-5

5.2.1. Assumptions and Rationale

5.2.2. Germany

5.2.3. France

5.2.4. Italy

5.2.5. Spain

5.2.6. United Kingdom

5.3. Japan

6. PSP Treatments and Medical Practices

7. Progressive Supranuclear Palsy Emerging Therapies

7.1. Key Cross Competition

7.2. AZP2006: AlzProtect

7.3. UCB0107: UCB Biopharma and

7.4. Emeramide (NBMI): EmeraMed

8. Failed Therapies

8.1. Gosuranemab/BIIB092: Biogen

8.2. ABBV-8E12: Abbvie

9. Progressive Supranuclear Palsy Market Size

10. 7MM: Country-Wise Market Analysis

10.1. United States Market Size

10.2. Germany Market Size

10.3. France Market Size

10.4. Italy Market Size

10.5. Spain Market Size

10.6. United Kingdom Market Size

10.7. Japan Market Size

11. Market Drivers

12. Market Barriers

13. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
SOURCE DelveInsight


Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States